SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers

Hypoxic environment is a prognostic factor linked in pediatric cancers to a worse outcome, favoring tumor progression and resistance to treatments. The activation of mechanistic Target Of Rapamycin (mTor)/hypoxia inducible factor (HIF)-1 pathway can be targeted by rapamycin and irinotecan, respectiv...

Full description

Bibliographic Details
Main Authors: Sarah Jannier, Véronique Kemmel, Consuelo Sebastia Sancho, Agathe Chammas, Amelia-Naomie Sabo, Erwan Pencreach, Françoise Farace, Marie Pierre Chenard, Benoit Lhermitte, Birgit Geoerger, Isabelle Aerts, Didier Frappaz, Pierre Leblond, Nicolas André, Stephane Ducassou, Nadège Corradini, Anne Isabelle Bertozzi, Eric Guérin, Florence Vincent, Michel Velten, Natacha Entz-Werle
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
intra-tumor hypoxia
mTor
HIF1
pediatric refractory cancers
Online Access:https://www.mdpi.com/2072-6694/12/10/3051

Internet

https://www.mdpi.com/2072-6694/12/10/3051

Similar Items